The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study)
Background Cachexia, characterized by involuntary muscle mass loss, negatively impacts survival outcomes, treatment tolerability, and functionality in cancer patients. However, there is a limited appreciation of the true prevalence of low muscle mass due to inconsistent diagnostic methods and limite...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2022-04, Vol.30 (4), p.3119-3129 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3129 |
|---|---|
| container_issue | 4 |
| container_start_page | 3119 |
| container_title | Supportive care in cancer |
| container_volume | 30 |
| creator | Raynard, Bruno Pigneur, Frederic Di Palma, Mario Deluche, Elise Goldwasser, François |
| description | Background
Cachexia, characterized by involuntary muscle mass loss, negatively impacts survival outcomes, treatment tolerability, and functionality in cancer patients. However, there is a limited appreciation of the true prevalence of low muscle mass due to inconsistent diagnostic methods and limited oncologist awareness.
Methods
Twenty-nine French healthcare establishments participated in this cross-sectional study, recruiting patients with those metastatic cancers most frequently encountered in routine practice (colon, breast, kidney, lung, prostate). The primary outcome was low skeletal muscle mass prevalence, as diagnosed by estimating the skeletal mass index (SMI) in the middle of the third-lumbar vertebrae (L3) level via computed tomography (CT). Other objectives included an evaluation of nutritional management, physical activity, and toxicities related to ongoing treatment.
Results
Seven hundred sixty-six patients (49.9% males) were enrolled with a mean age of 65.0 years
.
Low muscle mass prevalence was 69.1%. Only one-third of patients with low skeletal muscle mass were receiving nutritional counselling and only 28.4% were under nutritional management (oral supplements, enteral or parenteral nutrition). Physicians highly underdiagnosed those patients identified with low skeletal muscle mass, as defined by the primary objective, by 74.3% and 44.9% in obese and non-obese patients, respectively. Multivariate analyses revealed a lower risk of low skeletal muscle mass for females (OR: 0.22,
P
|
| doi_str_mv | 10.1007/s00520-021-06603-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8857123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A694276818</galeid><sourcerecordid>A694276818</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-4f711994ea4adda7c36571e8fa4620f2fef4f0fb6a46e04e4cb0c64284c4e7733</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEokPhBVggS2zKIsV_sRMWlUYjCkgVLBjWlse5nnFJ4sFOWvVBeF_uzJTSIoSyiGx_51z73lMULxk9ZZTqt5nSitOSclZSpago6aNixqQQpRaieVzMaCNZKUVVHRXPcr6klGld8afFkZC14pWuZ8XP5QbINsGV7WBwQKIni2XZgg8DtKSL1yR_hw5G25F-yq4D0tucSRjI1o4BhjGT6zBuSI9IHnHLEWfRKL0jlrgUcy4zuDHEYe_QIYAiSOQ8Yb0NyePU3pCTEW_xdTH_fFi_eV488bbL8OL2f1x8O3-_XHwsL758-LSYX5SukmwspdeMNY0EK23bWu2EqjSD2lupOPXcg5ee-pXCNVAJ0q2oU5LX0knQ2KTj4uzgu51WPbS7qyXbmW0KvU03JtpgHp4MYWPW8crUNRbiO4OTW4MUf0yQR9OH7KDr7ABxyoYrqhrBFNWIvv4LvYxTwrbsKEElq1l9j1rjQEwYfMS6bmdq5qqRXCvEkDr9B4VfC31wccDx4f4DAT8I9iNJ4O_eyKjZhckcwmQwTGYfJkNR9Op-d-4kv9ODgDgAGY-GNaQ_T_qP7S-_2NXX</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2630418187</pqid></control><display><type>article</type><title>The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study)</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Raynard, Bruno ; Pigneur, Frederic ; Di Palma, Mario ; Deluche, Elise ; Goldwasser, François</creator><creatorcontrib>Raynard, Bruno ; Pigneur, Frederic ; Di Palma, Mario ; Deluche, Elise ; Goldwasser, François</creatorcontrib><description>Background
Cachexia, characterized by involuntary muscle mass loss, negatively impacts survival outcomes, treatment tolerability, and functionality in cancer patients. However, there is a limited appreciation of the true prevalence of low muscle mass due to inconsistent diagnostic methods and limited oncologist awareness.
Methods
Twenty-nine French healthcare establishments participated in this cross-sectional study, recruiting patients with those metastatic cancers most frequently encountered in routine practice (colon, breast, kidney, lung, prostate). The primary outcome was low skeletal muscle mass prevalence, as diagnosed by estimating the skeletal mass index (SMI) in the middle of the third-lumbar vertebrae (L3) level via computed tomography (CT). Other objectives included an evaluation of nutritional management, physical activity, and toxicities related to ongoing treatment.
Results
Seven hundred sixty-six patients (49.9% males) were enrolled with a mean age of 65.0 years
.
Low muscle mass prevalence was 69.1%. Only one-third of patients with low skeletal muscle mass were receiving nutritional counselling and only 28.4% were under nutritional management (oral supplements, enteral or parenteral nutrition). Physicians highly underdiagnosed those patients identified with low skeletal muscle mass, as defined by the primary objective, by 74.3% and 44.9% in obese and non-obese patients, respectively. Multivariate analyses revealed a lower risk of low skeletal muscle mass for females (OR: 0.22,
P
<
0.01
) and those without brain metastasis (OR: 0.34,
P
<
0.01
). Low skeletal muscle mass patients were more likely to have delayed treatment administration due to toxicity (11.9% versus 6.8%,
P
=
0.04
).
Conclusions
There is a critical need to raise awareness of low skeletal muscle mass diagnosis among oncologists, and for improvements in nutritional management and physical therapies of cancer patients to curb potential cachexia. This calls for cross-disciplinary collaborations among oncologists, nutritionists, physiotherapists, and radiologists.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-021-06603-0</identifier><identifier>PMID: 34862578</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Analysis ; Body composition ; Breast cancer ; Cancer ; Care and treatment ; Colorectal cancer ; Cross-Sectional Studies ; CT imaging ; Diagnostic imaging ; Exercise ; Female ; Health aspects ; Humans ; Kidney cancer ; Lung cancer ; Male ; Medicine ; Medicine & Public Health ; Metastasis ; Muscle, Skeletal - pathology ; Muscles ; Musculoskeletal system ; Neoplasms - epidemiology ; Neoplasms - pathology ; Neoplasms - therapy ; Nursing ; Nursing Research ; Oncology ; Oncology, Experimental ; Original ; Original Article ; Pain Medicine ; Prevalence ; Prostate cancer ; Rehabilitation Medicine ; Sarcopenia - diagnostic imaging ; Sarcopenia - epidemiology ; Sarcopenia - etiology ; Tomography ; Tomography, X-Ray Computed - methods</subject><ispartof>Supportive care in cancer, 2022-04, Vol.30 (4), p.3119-3129</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>COPYRIGHT 2022 Springer</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-4f711994ea4adda7c36571e8fa4620f2fef4f0fb6a46e04e4cb0c64284c4e7733</citedby><cites>FETCH-LOGICAL-c541t-4f711994ea4adda7c36571e8fa4620f2fef4f0fb6a46e04e4cb0c64284c4e7733</cites><orcidid>0000-0001-7831-2440</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-021-06603-0$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-021-06603-0$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34862578$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raynard, Bruno</creatorcontrib><creatorcontrib>Pigneur, Frederic</creatorcontrib><creatorcontrib>Di Palma, Mario</creatorcontrib><creatorcontrib>Deluche, Elise</creatorcontrib><creatorcontrib>Goldwasser, François</creatorcontrib><title>The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study)</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Background
Cachexia, characterized by involuntary muscle mass loss, negatively impacts survival outcomes, treatment tolerability, and functionality in cancer patients. However, there is a limited appreciation of the true prevalence of low muscle mass due to inconsistent diagnostic methods and limited oncologist awareness.
Methods
Twenty-nine French healthcare establishments participated in this cross-sectional study, recruiting patients with those metastatic cancers most frequently encountered in routine practice (colon, breast, kidney, lung, prostate). The primary outcome was low skeletal muscle mass prevalence, as diagnosed by estimating the skeletal mass index (SMI) in the middle of the third-lumbar vertebrae (L3) level via computed tomography (CT). Other objectives included an evaluation of nutritional management, physical activity, and toxicities related to ongoing treatment.
Results
Seven hundred sixty-six patients (49.9% males) were enrolled with a mean age of 65.0 years
.
Low muscle mass prevalence was 69.1%. Only one-third of patients with low skeletal muscle mass were receiving nutritional counselling and only 28.4% were under nutritional management (oral supplements, enteral or parenteral nutrition). Physicians highly underdiagnosed those patients identified with low skeletal muscle mass, as defined by the primary objective, by 74.3% and 44.9% in obese and non-obese patients, respectively. Multivariate analyses revealed a lower risk of low skeletal muscle mass for females (OR: 0.22,
P
<
0.01
) and those without brain metastasis (OR: 0.34,
P
<
0.01
). Low skeletal muscle mass patients were more likely to have delayed treatment administration due to toxicity (11.9% versus 6.8%,
P
=
0.04
).
Conclusions
There is a critical need to raise awareness of low skeletal muscle mass diagnosis among oncologists, and for improvements in nutritional management and physical therapies of cancer patients to curb potential cachexia. This calls for cross-disciplinary collaborations among oncologists, nutritionists, physiotherapists, and radiologists.</description><subject>Aged</subject><subject>Analysis</subject><subject>Body composition</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Colorectal cancer</subject><subject>Cross-Sectional Studies</subject><subject>CT imaging</subject><subject>Diagnostic imaging</subject><subject>Exercise</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Kidney cancer</subject><subject>Lung cancer</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Muscle, Skeletal - pathology</subject><subject>Muscles</subject><subject>Musculoskeletal system</subject><subject>Neoplasms - epidemiology</subject><subject>Neoplasms - pathology</subject><subject>Neoplasms - therapy</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Original</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Prevalence</subject><subject>Prostate cancer</subject><subject>Rehabilitation Medicine</subject><subject>Sarcopenia - diagnostic imaging</subject><subject>Sarcopenia - epidemiology</subject><subject>Sarcopenia - etiology</subject><subject>Tomography</subject><subject>Tomography, X-Ray Computed - methods</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9ks1u1DAUhSMEokPhBVggS2zKIsV_sRMWlUYjCkgVLBjWlse5nnFJ4sFOWvVBeF_uzJTSIoSyiGx_51z73lMULxk9ZZTqt5nSitOSclZSpago6aNixqQQpRaieVzMaCNZKUVVHRXPcr6klGld8afFkZC14pWuZ8XP5QbINsGV7WBwQKIni2XZgg8DtKSL1yR_hw5G25F-yq4D0tucSRjI1o4BhjGT6zBuSI9IHnHLEWfRKL0jlrgUcy4zuDHEYe_QIYAiSOQ8Yb0NyePU3pCTEW_xdTH_fFi_eV488bbL8OL2f1x8O3-_XHwsL758-LSYX5SukmwspdeMNY0EK23bWu2EqjSD2lupOPXcg5ee-pXCNVAJ0q2oU5LX0knQ2KTj4uzgu51WPbS7qyXbmW0KvU03JtpgHp4MYWPW8crUNRbiO4OTW4MUf0yQR9OH7KDr7ABxyoYrqhrBFNWIvv4LvYxTwrbsKEElq1l9j1rjQEwYfMS6bmdq5qqRXCvEkDr9B4VfC31wccDx4f4DAT8I9iNJ4O_eyKjZhckcwmQwTGYfJkNR9Op-d-4kv9ODgDgAGY-GNaQ_T_qP7S-_2NXX</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Raynard, Bruno</creator><creator>Pigneur, Frederic</creator><creator>Di Palma, Mario</creator><creator>Deluche, Elise</creator><creator>Goldwasser, François</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7831-2440</orcidid></search><sort><creationdate>20220401</creationdate><title>The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study)</title><author>Raynard, Bruno ; Pigneur, Frederic ; Di Palma, Mario ; Deluche, Elise ; Goldwasser, François</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-4f711994ea4adda7c36571e8fa4620f2fef4f0fb6a46e04e4cb0c64284c4e7733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Analysis</topic><topic>Body composition</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Colorectal cancer</topic><topic>Cross-Sectional Studies</topic><topic>CT imaging</topic><topic>Diagnostic imaging</topic><topic>Exercise</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Kidney cancer</topic><topic>Lung cancer</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Muscle, Skeletal - pathology</topic><topic>Muscles</topic><topic>Musculoskeletal system</topic><topic>Neoplasms - epidemiology</topic><topic>Neoplasms - pathology</topic><topic>Neoplasms - therapy</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Original</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Prevalence</topic><topic>Prostate cancer</topic><topic>Rehabilitation Medicine</topic><topic>Sarcopenia - diagnostic imaging</topic><topic>Sarcopenia - epidemiology</topic><topic>Sarcopenia - etiology</topic><topic>Tomography</topic><topic>Tomography, X-Ray Computed - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raynard, Bruno</creatorcontrib><creatorcontrib>Pigneur, Frederic</creatorcontrib><creatorcontrib>Di Palma, Mario</creatorcontrib><creatorcontrib>Deluche, Elise</creatorcontrib><creatorcontrib>Goldwasser, François</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database (ProQuest)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raynard, Bruno</au><au>Pigneur, Frederic</au><au>Di Palma, Mario</au><au>Deluche, Elise</au><au>Goldwasser, François</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study)</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>30</volume><issue>4</issue><spage>3119</spage><epage>3129</epage><pages>3119-3129</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Background
Cachexia, characterized by involuntary muscle mass loss, negatively impacts survival outcomes, treatment tolerability, and functionality in cancer patients. However, there is a limited appreciation of the true prevalence of low muscle mass due to inconsistent diagnostic methods and limited oncologist awareness.
Methods
Twenty-nine French healthcare establishments participated in this cross-sectional study, recruiting patients with those metastatic cancers most frequently encountered in routine practice (colon, breast, kidney, lung, prostate). The primary outcome was low skeletal muscle mass prevalence, as diagnosed by estimating the skeletal mass index (SMI) in the middle of the third-lumbar vertebrae (L3) level via computed tomography (CT). Other objectives included an evaluation of nutritional management, physical activity, and toxicities related to ongoing treatment.
Results
Seven hundred sixty-six patients (49.9% males) were enrolled with a mean age of 65.0 years
.
Low muscle mass prevalence was 69.1%. Only one-third of patients with low skeletal muscle mass were receiving nutritional counselling and only 28.4% were under nutritional management (oral supplements, enteral or parenteral nutrition). Physicians highly underdiagnosed those patients identified with low skeletal muscle mass, as defined by the primary objective, by 74.3% and 44.9% in obese and non-obese patients, respectively. Multivariate analyses revealed a lower risk of low skeletal muscle mass for females (OR: 0.22,
P
<
0.01
) and those without brain metastasis (OR: 0.34,
P
<
0.01
). Low skeletal muscle mass patients were more likely to have delayed treatment administration due to toxicity (11.9% versus 6.8%,
P
=
0.04
).
Conclusions
There is a critical need to raise awareness of low skeletal muscle mass diagnosis among oncologists, and for improvements in nutritional management and physical therapies of cancer patients to curb potential cachexia. This calls for cross-disciplinary collaborations among oncologists, nutritionists, physiotherapists, and radiologists.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34862578</pmid><doi>10.1007/s00520-021-06603-0</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7831-2440</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2022-04, Vol.30 (4), p.3119-3129 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8857123 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Analysis Body composition Breast cancer Cancer Care and treatment Colorectal cancer Cross-Sectional Studies CT imaging Diagnostic imaging Exercise Female Health aspects Humans Kidney cancer Lung cancer Male Medicine Medicine & Public Health Metastasis Muscle, Skeletal - pathology Muscles Musculoskeletal system Neoplasms - epidemiology Neoplasms - pathology Neoplasms - therapy Nursing Nursing Research Oncology Oncology, Experimental Original Original Article Pain Medicine Prevalence Prostate cancer Rehabilitation Medicine Sarcopenia - diagnostic imaging Sarcopenia - epidemiology Sarcopenia - etiology Tomography Tomography, X-Ray Computed - methods |
| title | The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T00%3A57%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20prevalence%20of%20CT-defined%20low%20skeletal%20muscle%20mass%20in%20patients%20with%20metastatic%20cancer:%20a%20cross-sectional%20multicenter%20French%20study%20(the%20SCAN%20study)&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Raynard,%20Bruno&rft.date=2022-04-01&rft.volume=30&rft.issue=4&rft.spage=3119&rft.epage=3129&rft.pages=3119-3129&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-021-06603-0&rft_dat=%3Cgale_pubme%3EA694276818%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2630418187&rft_id=info:pmid/34862578&rft_galeid=A694276818&rfr_iscdi=true |